Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Interest Expenses (2016 - 2017)

Historic Interest Expenses for Pharma (IGC) over the last 9 years, with Q4 2017 value amounting to $60527.0.

  • Pharma's Interest Expenses rose 3026.36% to $60527.0 in Q4 2017 from the same period last year, while for Sep 2018 it was $60527.0, marking a year-over-year decrease of 7234.77%. This contributed to the annual value of $223464.0 for FY2017, which is 445.76% up from last year.
  • As of Q4 2017, Pharma's Interest Expenses stood at $60527.0, which was up 3026.36% from $40832.0 recorded in Q3 2017.
  • Pharma's 5-year Interest Expenses high stood at $504932.0 for Q1 2013, and its period low was $33928.0 during Q1 2016.
  • For the 5-year period, Pharma's Interest Expenses averaged around $83559.4, with its median value being $60848.5 (2014).
  • In the last 5 years, Pharma's Interest Expenses skyrocketed by 188046.02% in 2013 and then plummeted by 8850.26% in 2014.
  • Quarter analysis of 5 years shows Pharma's Interest Expenses stood at $52502.0 in 2013, then increased by 18.01% to $61957.0 in 2014, then fell by 17.68% to $51000.0 in 2015, then decreased by 8.89% to $46465.0 in 2016, then skyrocketed by 30.26% to $60527.0 in 2017.
  • Its last three reported values are $60527.0 in Q4 2017, $40832.0 for Q3 2017, and $44546.0 during Q2 2017.